Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
P/E ratio for Roche Holding AG (ROG.SW)
P/E ratio as of 2023: 16.99
According to Roche Holding AG's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.99. At the end of 2022 the company had a P/E ratio of 18.71.
P/E ratio history for Roche Holding AG from 1998 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 16.99 |
| 2022 | 18.71 |
| 2021 | 23.13 |
| 2020 | 18.48 |
| 2019 | 19.91 |
| 2018 | 20.27 |
| 2017 | 24.36 |
| 2016 | 20.69 |
| 2015 | 26.54 |
| 2014 | 24.55 |
| 2013 | 18.93 |
| 2012 | 16.85 |
| 2011 | 14.47 |
| 2010 | 13.52 |
| 2009 | 19.61 |
| 2008 | 15.58 |
| 2007 | 17.21 |
| 2006 | 23.62 |
| 2005 | 24.77 |
| 2004 | 16.57 |
| 2003 | 34.10 |
| 2002 | -20.07 |
| 2001 | 26.93 |
| 2000 | 16.04 |
| 1999 | 27.41 |
| 1998 | 31.90 |